[1] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
[2] World Health Organization. https://www.who.int/emergencies/diseases/novel coronavirus–2019Accessed Feb 7, 2020.
[3] Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nature reviews. Microbiology.2019;17:181–92.
[4] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733.
[5] Jiang, Y, Xu, J, Zhou, C, Wu, Z, Zhong, S, Liu, J, et al. Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. Am J RespirCrit Care Med. 2005; 171, 850–857.
[6] Niu, P, Zhao, G, Deng, Y, Sun, S, Wang, W, Zhou, Y, et al. A novel human mAb (MERS-GD27) provides prophylactic and postexposure efficacy in MERS-CoV susceptible mice. Sci China Life Sci. 2018; 61, 1280–1282
[7] Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.NEngl J Med. 2020; doi: 10.1056/NEJMoa2001316.
[8] NHC. http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df3517 da8aefc2.shtml. (accessed Feb 19, 2020)
[9] Pan Y, Guan H, Zhou S, Wang Y, Li Q, Zhu T, et al. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. EurRadiol. 2020. doi: 10.1007/s00330–020–06731-x.
[10] Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT-PCR Testing. Radiology. 2020. doi: 10.1148/radiol.2020200343.
[11] WHO. Novel coronavirus-China. Jan 12, 2020. http://www.who.int/csr/don/ 12-january–2020-novel-coronavirus-china/en/ (accessedJan 19, 2020).
[12] Bi, Y, Tan, S, Yang, Y, Wong, G, Zhao, M, Zhang, Q, et al. Clinical and immunological characteristics of human infections with H5N6 avian influenza virus. Clin Infect Dis. 2019; 68, 1100–1109.
[13] Sanz F, Gimeno C, Lloret T, et al. Relationship between thepresence of hypoxemia and the inflammatory response measuredby C-reactive protein in bacteremic pneumococcal pneumonia.EurRespir J. 2011; 38: 2492.
[14] Hui, D. S. C.; Zumla, A. Severe acute respiratory syndrome: Historical, epidemiologic, and clinical features. Infect. Dis. Clin. North Am. 2019, 33, 869–889.
[15] Killerby, ME.; Biggs, HM.; Midgley, CM.; Gerber, SI.; Watson, JT. Middle East respiratory syndrome coronavirus transmission. Emerg. Infect. Dis. 2020, 26, 191–198.
[16] Nikkei Asian Review.https://asia.nikkei.com/Spotlight/Coronavirusoutbreak/ CoronaviruslatestUScitizendiesinWuhanafterinfection.Accessed February 8, 2020.
[17] CNN Business. https://edition.cnn.com/2020/01/31/economy/chinaeconomy- coronavirus/index.html.Accessed February 9, 2020.
[18] Guan WJ, Ni ZY, Hu Y, Liang WH, OuCQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China.NEngl J Med. 2020; doi: 10.1056/NEJMoa2002032.
[19] Leung WK, To KF, Chan PK, Chan HL, Wu AK, Lee N, et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology 2003; 125: 1011–7.
[20] Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013; 13: 752–61.
[21] MahallawiWH, Khabour OF, Zhang Q, Makhdoum HM, Suliman BA. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine 2018; 104: 8–13.
[22] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.Lancet. 2020;395:507–513.
[23] Wong CK, Lam CWK, Wu AKL, Ip WK, Lee NL, Chan IH, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. ClinExpImmunol 2004; 136: 95–103.
[24] Liu WJ, Zhao M, Liu K, Xu K4, Wong G5, Tan W, et al. T-cell immunity of SARS-CoV: implications for vaccine development against MERS-CoV. Antiviral Res 2017; 137: 82–92.
[25] Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020.doi: 10.1007/s11427–020–1643–8.
[26] Arabi YM, Alothman A, Balkhy HH, Al-Dawood A, AlJohani S, Al Harbi S, et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials 2018; 19: 81.
[27] Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID–19):A multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020; pii: S0163–4453(20)30099–2. doi: 10.1016/j.jinf.2020.02.016.